PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IS ASSOCIATED WITH LP(A) IN TYPE 2 DIABETIC PATIENTS

被引：2
|
作者：
Nekaies, Y. [1 ]
Baudin, B. [2 ,3 ]
Sakly, M. [1 ]
Attia, N. [1 ]
机构：
[1] Univ Carthage, Fac Sci Bizerte, Res Unit Integrated Physiol UR11ES33, Bizerte, Tunisia
[2] Biol & Pathol Pole St Antoine Hosp, Dept Biochem, Paris, France
[3] Fac Pharm Chatenay Malabry, Paris, France
来源：
ATHEROSCLEROSIS | 2015年 / 241卷 / 01期
关键词：
D O I：
10.1016/j.atherosclerosis.2015.04.356
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS-0862
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [41] The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
    Ben Zadok, O. Itzhaki
    Mager, A.
    Leshem-Lev, D.
    Lev, E.
    Kornowski, R.
    Eisen, A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1828 - 1828
  • [42] Proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels are associated with the metabolic syndrome in patients with stable coronary artery disease
    Caselli, C.
    Ragusa, R.
    Del Turco, S.
    Basta, G.
    Saraste, A.
    Knuuti, J.
    De Caterina, R.
    Neglia, D.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3802 - 3802
  • [43] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Huimin Sun
    Wen Meng
    Jie Zhu
    Lu Wang
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 643 - 658
  • [44] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons
    Yadav, K.
    Sharma, M.
    Ferdinand, K. C.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2016, 26 (10) : 853 - 862
  • [45] Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels Another Piece of the Puzzle
    Paquette, Martine
    Baass, Alexis
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (05):
  • [46] Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19
    Mester, Patricia
    Amend, Pablo
    Schmid, Stephan
    Mueller, Martina
    Buechler, Christa
    Pavel, Vlad
    VIRUSES-BASEL, 2023, 15 (07):
  • [47] Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After LDL Apheresis
    Tavori, Hagai
    Giunzioni, Ilaria
    Linton, MacRae F.
    Fazio, Sergio
    CIRCULATION, 2013, 128 (22)
  • [48] Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
    Tavori, Hagai
    Giunzioni, Ilaria
    Linton, MacRae F.
    Fazio, Sergio
    CIRCULATION RESEARCH, 2013, 113 (12) : 1290 - +
  • [49] THE IMPACT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) ON SERUM LIPID PROFILE IN HEMODIALYSIS (HD) PATIENTS
    Arita, Kazuko
    Tanabe, Takehiro
    Kihara, Emi
    Maeda, Katsutoshi
    Oda, Hiroaki
    Doi, Shigehiro
    Masaki, Takao
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 293 - 293
  • [50] Proprotein Convertase Subtilisin/Kexin Type 9
    Lu
    Daugherty
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (04) : E32 - E32
12345